1. Home
  2. PMCB vs ATXG Comparison

PMCB vs ATXG Comparison

Compare PMCB & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

N/A

Current Price

$0.37

Market Cap

4.0M

Sector

Health Care

ML Signal

N/A

Logo Addentax Group Corp.

ATXG

Addentax Group Corp.

N/A

Current Price

$2.70

Market Cap

4.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
PMCB
ATXG
Founded
1996
2014
Country
United States
China
Employees
2
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
4.5M
IPO Year
2001
2015

Fundamental Metrics

Financial Performance
Metric
PMCB
ATXG
Price
$0.37
$2.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 99.3K
19.0K
Earning Date
12-17-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.30
$0.28
52 Week High
$1.51
$9.56

Technical Indicators

Market Signals
Indicator
PMCB
ATXG
Relative Strength Index (RSI) 50.38 40.76
Support Level $0.32 $2.50
Resistance Level $0.40 $3.97
Average True Range (ATR) 0.04 0.35
MACD 0.01 -0.01
Stochastic Oscillator 58.20 59.05

Price Performance

Historical Comparison
PMCB
ATXG

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services and Consulting. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

Share on Social Networks: